Analyst Ratings For NASDAQ:TXMD – TherapeuticsMD (NASDAQ:TXMD)
Today, JPMorgan Chase & Co. initiated coverage on NASDAQ:TXMD – TherapeuticsMD (NASDAQ:TXMD) with a Overweight with a price target of $11.00.
Some recent analyst ratings include
- 6/15/2018-JPMorgan Chase & Co. initiated coverage with a Overweight rating.
- 3/9/2018-Noble Financial Reiterated Rating of Buy.
- 1/7/2018-Cantor Fitzgerald Reiterated Rating of Buy.
- 11/6/2017-Cowen Reiterated Rating of Outperform.
- 9/26/2017-Jefferies Financial Group Reiterated Rating of Buy.
Recent Insider Trading Activity For NASDAQ:TXMD – TherapeuticsMD (NASDAQ:TXMD)
NASDAQ:TXMD – TherapeuticsMD (NASDAQ:TXMD) has insider ownership of 22.85% and institutional ownership of 72.70%.
- On 12/8/2017 Tommy G Thompson, Director, bought 5,000 with an average share price of $6.21 per share and the total transaction amounting to $31,050.00.
- On 8/30/2017 Tommy G Thompson, Director, bought 5,000 with an average share price of $5.99 per share and the total transaction amounting to $29,950.00.
- On 3/11/2016 Cooper C Collins, Director, bought 16,000 with an average share price of $6.23 per share and the total transaction amounting to $99,680.00.
- On 8/25/2015 Angus C Russell, Director, bought 13,500 with an average share price of $5.98 per share and the total transaction amounting to $80,730.00.
- On 6/8/2015 Mitchell Krassan, EVP, sold 30,000 with an average share price of $8.18 per share and the total transaction amounting to $245,400.00.
- On 5/12/2015 Angus C Russell, Director, bought 35,000 with an average share price of $6.15 per share and the total transaction amounting to $215,250.00.
- On 5/11/2015 Tommy G Thompson, Chairman, bought 6,000 with an average share price of $6.09 per share and the total transaction amounting to $36,540.00.
Recent Trading Activity for NASDAQ:TXMD – TherapeuticsMD (NASDAQ:TXMD)
Shares of NASDAQ:TXMD – TherapeuticsMD closed the previous trading session at 7.10 up +0.22 3.20% with 7.409999847412109 shares trading hands.